Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
Completed
- Conditions
- Neisseria Meningitidis
- Interventions
- Biological: MenBvac
- Registration Number
- NCT01621945
- Lead Sponsor
- University Hospital, Rouen
- Brief Summary
The main objective of the study is to estimate the proportion of children, born between the 06/04/2004 and the 17/004/2008, living around Neufchatel en Bray, vaccinated by MenBVac, with a serum bactericidal activity against B:14,P1-7,16 clone related to a protection (\>= 4), before the fourth dose of MenBvac and after: 6 weeks and one year after the fourth dose.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- children born between 06/04/2004 and 17/04/2008, living in Neufchatel en Bray,and Having participated to the first study,
- children who Have to be Vaccinated MenBVac® for the four times,
- parental authority(ies)assent.
Exclusion Criteria
- no parental authority(ies)assent,
- no blood sample,
- impossibility of fourth vaccination,
- children yet vaccinated or non eligible for vaccination.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Bras A MenBvac children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac
- Primary Outcome Measures
Name Time Method Vaccine Immunity after the fourth dose of MenbVac Assessment of vaccine Immunity with measure of percentage of children who have hSBA title \>= 4 six weeks after the fourth dose of vaccine
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Maison Du Département
🇫🇷Neufchâtel En Bray, France